News and commentary from the world of neurology and neuroscience
Small study suggested benefits for MS patients with chronic optic neuropathy
Blood samples reveal signs of MS years before clinical diagnosis
Half of patients had no evidence of disease activity at 48 weeks
Discontinuing natalizumab and fingolimod carried highest risk
No negative effects on early infant development or health seen
Higher tolebrutinib dose, longer treatment duration may be needed
No efficacy difference between the two drugs in two phase III trials
Processing speed scores lower 4 years later for people with one or more baseline lesions